# Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results
Ticker: SNGX
Company: SOLIGENIX
Source: SOLIGENIX
Published: 2026-05-08 11:30 EST
Original Source URL: https://ir.soligenix.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-26 11:30 EST — [Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo](https://biopharmsignal.com/news/SNGX/suitability-of-vaccine-platform-for-bundibugyo-virus-cause-of-the-ebola-outbreak-in-congo) — Source: SOLIGENIX
- 2026-05-08 11:30 EST — [Soligenix Announces Recent Updates and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results) — Source: SOLIGENIX
- 2026-04-28 11:30 EST — [Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma](https://biopharmsignal.com/news/SNGX/soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybrytetm-in-treatment-of-cutaneous-t-cell-lymphoma) — Source: SOLIGENIX
- 2026-04-02 11:30 EST — [Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy](https://biopharmsignal.com/news/SNGX/positive-clinical-results-from-hybrytetm-comparative-study-evaluating-hybrytetm-against-valchlorr-in-the-treatment-of-cutaneous-t-cell-lymphoma-published-in-oncology-and-therapy) — Source: SOLIGENIX
- 2026-03-31 11:30 EST — [Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results](https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-accomplishments-and-year-end-2025-financial-results) — Source: SOLIGENIX
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)